Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 747-749

  Olin, Rebecca L ^a   Nichols, Kim E ^b   Naghashpour, Mojdeh ^c   Wasik, Mariusz ^c   Shelly, Brenda ^a   Stadtmauer, Edward A ^a   Vogl, Dan T ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FERRITIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR; STEROID; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HYPERKALEMIA; INFLAMMATORY DISEASE; KIDNEY FAILURE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PRIORITY JOURNAL; RELAPSE; REPEATED DRUG DOSE; STEROID THERAPY; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DOXORUBICIN; FERRITINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; T-LYMPHOCYTE SUBSETS; VINCRISTINE;

EID: 51449098773     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21236     Document Type: Article

References (12)

1. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: Diagnosis, pathophysiology, treatment, and future perspectives. Ann Med 2006;38:20-31.
2. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131.
3. Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol 1993;15:92-98.
4. Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: A useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 1995;86:4706-4707.
5. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol 2007;27:1-18.
6. Lackner H, Urban C, Sovinz P, et al. Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. Haematologica 2008;93:291-294.
7. Prahalad S, Bove KE, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001;28:2120-2124.
8. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 2001;7:252-256.
9. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 2006;81:59-61.
10. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-2075.
11. Tomaske M, Amon O, Bosk A, et al. Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 2002;38:141-142.
12. Chan EY, Pi D, Chan GT, et al. Peripheral T-cell lymphoma presenting as hemophagocytic syndrome. Hematol Oncol 1989;7:275-285.